[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 106,947,024
  • Shares Outstanding, K 2,025,128
  • Annual Sales, $ 43,078 M
  • Annual Income, $ 7,538 M
  • EBIT $ 10,759 M
  • EBITDA $ 13,810 M
  • 60-Month Beta 0.36
  • Price/Sales 2.47
  • Price/Cash Flow 8.74
  • Price/Book 4.54

Options Overview Details

View History
  • Implied Volatility 29.62% (+0.92%)
  • Historical Volatility 23.68%
  • IV Percentile 66%
  • IV Rank 29.34%
  • IV High 61.51% on 10/23/25
  • IV Low 16.39% on 12/08/25
  • Expected Move (DTE 2) 0.68 (1.30%)
  • Put/Call Vol Ratio 3.98
  • Today's Volume 4,296
  • Volume Avg (30-Day) 5,228
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 67,949
  • Open Int (30-Day) 60,170
  • Expected Range 51.74 to 53.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.27
  • Number of Estimates 5
  • High Estimate $1.30
  • Low Estimate $1.25
  • Prior Year $1.23
  • Growth Rate Est. (year over year) +3.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.57 +7.93%
on 06/02/26
53.45 -1.93%
on 06/12/26
+1.88 (+3.72%)
since 05/29/26
3-Month
48.57 +7.93%
on 06/02/26
59.57 -12.00%
on 04/14/26
-1.81 (-3.34%)
since 03/30/26
52-Week
35.45 +47.87%
on 07/17/25
61.69 -15.03%
on 02/18/26
+14.02 (+36.51%)
since 06/30/25

Most Recent Stories

More News
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 42.06 (-0.71%)
AZN : 189.62 (-0.70%)
MRK : 128.50 (-0.68%)
GILD : 126.34 (+0.01%)
TEM : 57.93 (-0.65%)
GSK : 52.42 (-0.74%)
ARKK : 80.82 (+0.24%)
BMY : 57.62 (-1.61%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment 1 ...

SPRO : 2.21 (-2.21%)
GSK.LN : 1,981.000 (+0.08%)
GSK : 52.42 (-0.74%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs...

SPRO : 2.21 (-2.21%)
GSK.LN : 1,981.000 (+0.08%)
GSK : 52.42 (-0.74%)
MarketBeat Week in Review – 06/08 - 06/12

Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum

NVDA : 200.09 (+2.63%)
GOOGL : 357.37 (+1.05%)
AAPL : 289.36 (+2.70%)
WING : 173.41 (+4.80%)
SPOT : 459.13 (-0.68%)
CBRL : 53.30 (-1.19%)
P : 78.79 (+8.95%)
IREN : 45.73 (-0.39%)
TSLA : 420.60 (+2.13%)
SPCX : 170.86 (+4.06%)
INTC : 139.63 (+6.01%)
NUVL : 123.50 (-0.01%)
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

RHHVF : 414.1960 (-0.46%)
NUVL : 123.50 (-0.01%)
GSK : 52.42 (-0.74%)
PFE : 24.08 (-1.19%)
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc ...

NUVL : 123.50 (-0.01%)
GSK : 52.42 (-0.74%)
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

NUVL : 123.50 (-0.01%)
RHHBY : 51.3500 (-2.34%)
GSK : 52.42 (-0.74%)
PFE : 24.08 (-1.19%)
Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

NVDA : 200.09 (+2.63%)
AZN : 189.62 (-0.70%)
AMD : 580.91 (+7.68%)
ARM : 354.57 (+3.20%)
GSK : 52.42 (-0.74%)
TSM : 477.57 (+4.94%)
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

On-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK’s Ask2BSure...

GSK.LN : 1,981.000 (+0.08%)
GSK : 52.42 (-0.74%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 189.62 (-0.70%)
ABBV : 251.64 (-1.05%)
GSK : 52.42 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 54.08
2nd Resistance Point 53.39
1st Resistance Point 52.90
Last Price 52.42
1st Support Level 51.72
2nd Support Level 51.03
3rd Support Level 50.54

See More

52-Week High 61.69
Last Price 52.42
Fibonacci 61.8% 51.67
Fibonacci 50% 48.57
Fibonacci 38.2% 45.48
52-Week Low 35.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.